Carbon footprint of as-needed budesonide-formoterol in mild asthma: a post hoc analysis - Milan 2023

Inhaler devices: environmental impact, technique, and adherence

Chair(s): Omar S. Usmani, Dimitrios Toumpanakis

Session type: Poster session

Carbon footprint of as-needed budesonide-formoterol in mild asthma: a post hoc analysis

Lee Hatter

EVENTS HOME

Poster
Abstract

Previous presentation

Next presentation

Session content

Towards minimizing carbon footprint of triple fixed dose MDIs for severe asthmatic patients: relative lung bioavailability and total systemic exposure of a high dose formulation of BDP/FF/GB with novel propellant

Francois Rony

Poster

Abstract

Trends in inhaler use and associated carbon footprint: a sales data-based study in Europe

Alexander Wilkinson

Poster

Abstract

Characteristics and treatment pathways of COPD patients initiating single-inhaler dual or triple therapy in England

Stephen G Noorduyn

Poster

Abstract

Adherence to single and multiple inhaler triple therapies among patients with COPD in the real world in Japan

Kieran J. Rothnie

Poster

Abstract

An Algerian study on patients attitude towards inhalers

Redouene Sid Ahmed Benazzouz

Poster

Abstract

TRITRIAL study - TRIple Therapy in Real life: Impact on Adherence and HeaLth status in COPD patients in Italy.

Alessio Piraino

Poster

Abstract

Socioeconomic disparities in the carbon footprint of asthma care in the UK: results from SABINA CARBON

Ekaterina Maslova

Poster

Abstract

Switching inhaler treatment from pMDI to DPI in real-world; reduction of carbon footprint

Lauri Lehtimaki

Poster

Abstract

Are people with airways disease aware of the environmental impact of inhalers?

Maeve Savage

Poster

Abstract

Change in treatment adherence after three months of treatment with extrafine formulation single-inhaler triple therapy in patients with asthma: the TriMaximize study

Frederik Trinkmann

Poster

Abstract

Effect on asthma control in patients with asthma and concomitant COPD after three months of treatment with extrafine formulation single-inhaler triple therapy TriMaximize study

Hartmut Timmermann

Poster

Abstract

Carbon footprint of as-needed budesonide-formoterol in mild asthma: a post hoc analysis

Lee Hatter

Poster

Abstract

Preserving treatment for asthma and COPD patients while minimizing carbon footprint: relative lung bioavailability and total systemic exposure of a medium dose formulation of BDP/FF/GB MDI with novel propellant

Francois Rony

Poster

Abstract

Choice of Salbutamol Metered Dose Inhaler (MDI) type and use of a Spacer Impact Drug Delivery and Carbon Emissions

Mark Nagel

Poster

Abstract

Impact of extrafine formulation single-inhaler triple therapy on health-related quality of life after three months of treatment in patients with asthma: the TriMaximize study

Andreas Rembert Koczulla

Poster

Abstract

Impact of extrafine formulation single-inhaler triple therapy on lung function after three months of treatment in patients with asthma: the TriMaximize study

Christian Gessner

Poster

Abstract

Change in asthma control after three months of treatment with extrafine formulation single-inhaler triple therapy in patients with asthma: the TriMaximize study

Timm Greulich

Poster

Abstract

The trascendence of capsule transparence in dry powder inhalation devices in the treatment of COPD.

Rocio Reinoso Arija

Poster

Abstract

Have we taken any steps to reduce the environmental impacts of inhalers? A perspective from a specialist respiratory team in a deprived area of the UK

Djeyapraba Kadar

Poster

Abstract

A Real-World Evaluation of a Digital Self-Management and Adherence Support System in Patients with Severe Asthma

Laura Wiffen

Poster

Abstract

CDN Connection Issue

The ERS International Congress 2023, Milan

#{title}